Werewolf Therapeutics(HOWL) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update – Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting – – Encouraging signs of clinical activity at tolerable doses disclosed from ongoing Phase 1 clinical trial of WTX-330 – – Updated data on WTX-124 in combination with pembrolizumab and opening of expansion arms anticipated in the second half of 2024 – – Update on ...